Gladstone-UCSF Institute of Genomic Immunology Seminar
Tuesday, November 12, 2024

Robert Manguso, PhD

Principal Investigator and Assistant Professor of Medicine, Mass General Cancer Center and Harvard Medical School; CoDirector of Tumor Immunotherapy Discovery Engine and Associate Member, Broad Institute

Principal Investigator Robert Manguso, PhD, is an assistant professor of medicine at Massachusetts General Hospital Cancer Center and Harvard Medical School, and an associate member at the Broad Institute. He completed his undergraduate degree at Wheaton College in Norton, MA, and his PhD at Harvard Medical School/Dana-Farber Cancer Institute in Nick Haining’s lab. His work focuses on using functional genomics to improve our understanding of cancer immunology and the treatment of cancer with immunotherapies.

The Manguso Lab uses a range of approaches including mouse models, functional genomics, cellular immunology, and single-cell profiling to understand how cancers evade the immune system. The lab has pioneered the use of in vivo genetic screens with CRISPR to identify new immunotherapy targets and resistance mechanisms. Using these approaches, Manguso’s team identified the tyrosine phosphatase PTPN2, a critical regulator of immunotherapy sensitivity in tumor cells. They also identified the dsRNA-editing enzyme ADAR1 as a checkpoint that regulates the sensing of self-dsRNA by tumor cells. Results indicate there are dozens of ways that cancers can be targeted by the immune system, and the team is working to understand the new mechanisms revealed by their studies. In the long term, these approaches will enable a new understanding of how the immune system interacts with cancerous tissue and how the interaction can be manipulated to destroy tumors.

 

Details

Dates
November 12, 2024
Time
10:00-11:00am PST
Location
Mahley Auditorium & Online
Contact(s)







The Gladstone-UCSF Institute of Genomic Immunology Seminar Series showcases speakers at the intersection of genomic technology and immunology research with an aim to engineer the human immune system for therapeutic benefit. Speakers span technology development, synthetic biology, bioengineering, and the development and clinical application of immunotherapy. These talks are open to the Gladstone and UCSF communities.

Diversity, Equity, and Inclusion

At Gladstone, we are committed to providing events and professional development activities that resonate with our community’s diverse members. Our goal is to develop creative programming that encompasses a wide variety of ideas and perspectives to inspire, educate, and engage with everyone within our walls.

We want to effect positive change through our events and activities by providing a platform for discussions on important topics related to increasing diversity and inclusiveness in the sciences.